Pentixapharm Holding AG
PTP | F
Overview
Corporate Details
- ISIN(s):
- DE000A383RV0 (+1 more)
- LEI:
- 3912005VBOVXNDXEQZ36
- Country:
- Germany
- Address:
- Robert-Rössle-Straße, 10, 13125 Berlin
- Website:
- https://www.pentixapharm.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Pentixapharm is a clinical-stage radiopharmaceutical development company founded in 2019 with its offices in Berlin and W�rzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. The specific binding of the ligand to the pathological surface structure of the target cell is identical for both diagnosis and therapy, enabling a theranostic mode of action.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-06 00:00 |
Interim Report
Half-yearly financial report 2025
|
English | 723.4 KB | |
| 2025-07-24 14:04 |
Report Publication Announcement
|
English | 3.9 KB | |
| 2025-05-27 09:43 |
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
|
English | 10.0 KB | |
| 2025-05-08 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2025
|
English | 479.2 KB | |
| 2025-04-26 16:00 |
Report Publication Announcement
|
English | 3.8 KB | |
| 2025-04-25 00:00 |
Annual Report
Annual financial report 2024
|
English | 2.3 MB | |
| 2025-04-24 14:00 |
Regulatory News Service
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based Pentix…
|
English | 8.8 KB | |
| 2025-04-17 15:05 |
Pre-Annual General Meeting Information
Pentixapharm Holding AG: Bekanntmachung der Einberufung zur Hauptversammlung am…
|
German | 88.5 KB | |
| 2025-04-15 08:17 |
Report Publication Announcement
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guida…
|
English | 6.4 KB | |
| 2025-03-19 13:20 |
Report Publication Announcement
|
English | 3.9 KB | |
| 2025-03-18 13:20 |
Report Publication Announcement
|
English | 3.9 KB | |
| 2025-03-04 14:38 |
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
|
English | 6.4 KB | |
| 2025-03-03 14:38 |
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
|
English | 6.4 KB | |
| 2025-02-14 14:10 |
Regulatory News Service
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with …
|
English | 7.5 KB | |
| 2025-02-13 14:10 |
Regulatory News Service
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with …
|
English | 7.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
BioPorto | Denmark | BIOPOR | |
|
BioSenic SA | Belgium | BIOS | |
|
Biosergen AB | Sweden | BIOSGN | |
|
BIOTECH | Spain | BST | |
|
Biotest AG | Germany | BIO3 | |
|
Bioton S.A. | Poland | BIO | |
|
Bioversys N | Switzerland | BIOV | |
|
Biovica International B | Sweden | BIOVIC | |
|
Bonus BioGroup Ltd. | Israel | BONS | |
|
BRAIN Biotech AG | Germany | BNN |